CNTB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	52 083.00
Average Volume	168 251
Market Cap	98.08M
EPS	$0 ( 2024-04-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.650
ATR14	$0.0370 (2.08%)

Volume Correlation

Long: 0.03 (neutral)

Short: -0.37 (neutral)

Signal:(52.07) Neutral

Connect Biopharma Correlation

10 Most Positive Correlations
REPL	0.884
GGAL	0.881
NYMTP	0.878
NWLI	0.877
JOUT	0.874
ANPC	0.873
SIOX	0.872
OM	0.872
AMYT	0.871
HZNP	0.87

10 Most Negative Correlations
LARK	-0.9
HMNF	-0.888
RMRM	-0.882
PCRX	-0.879
THTX	-0.868
USCB	-0.866
MARK	-0.865
SNPX	-0.864
SSB	-0.859
GOSS	-0.858

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Connect Biopharma Correlation - Currency/Commodity

-0.29
( neutral )

0.39
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.20
( neutral )

-0.65
( weak negative )

Connect Biopharma Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-14.50

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-14.50

Financial Reports:

No articles found.

Connect Biopharma Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.